Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Micro-RNA Expression Profiles in High Risk Prostate Cancer

This study has been terminated.
Sponsor:
Collaborator:
Universitaire Ziekenhuizen Leuven
Information provided by:
Wuerzburg University Hospital
ClinicalTrials.gov Identifier:
NCT01220427
First received: October 12, 2010
Last updated: March 2, 2016
Last verified: August 2010

October 12, 2010
March 2, 2016
June 2007
Not Provided
Recurrence free survival [ Time Frame: Yearly update until clinical progression ] [ Designated as safety issue: No ]
The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly for until death.
Same as current
Complete list of historical versions of study NCT01220427 on ClinicalTrials.gov Archive Site
Cancer specific survival [ Time Frame: Yearly update until death ] [ Designated as safety issue: No ]
The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly until death.
Same as current
Not Provided
Not Provided
 
Micro-RNA Expression Profiles in High Risk Prostate Cancer
Micro-RNA Expression Profiles in High Risk Prostate Cancer
The purpose of this study is to determine whether specific Micro-RNA expression profiles are related to Prostate cancer outcome.
Not Provided
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
University hospital, community hospital
  • Prostate Cancer
  • Radical Prostatectomy
Not Provided
Clinical high-risk prostate cancer, radical prostatectomy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
300
Not Provided
Not Provided

Inclusion Criteria:

Patients with clinically localised high risk prostate cancer (cT>2, bx GS >7, PSA >20 ng/ml) scheduled for radical prostatectomy.

Exclusion Criteria:

Non high risk prostate cancer

Male
35 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01220427
mi-RNA HR-Pca
No
Not Provided
Not Provided
Martin Spahn, University Hospital Würzburg
Wuerzburg University Hospital
Universitaire Ziekenhuizen Leuven
Not Provided
Wuerzburg University Hospital
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP